PCSK9 Rejections
PCSK9 inhibitors help lower “bad” cholesterol. But access has remained a major hurdle, especially for at-risk populations. In recent years, Medicare has rejected more than half of patients for PCSK9 inhibitors.
Articles
Blacks, Hispanics, and Women at Higher Risk of Being Denied Life-Saving Medication
Black, Hispanic, and women patients in Arkansas are more likely to face insurance barriers when trying to access a cholesterol-lowering heart medicine, according to a new report.
Mississippians Need Open Access to Life-Saving Cardiovascular Treatments
Nearly one-third of Mississippians live with high cholesterol,” cardiologist Dr. Kevin Hall writes, warning that insurance companies are statistically more likely to deny life-saving medications for Black and hispanic cardiovascular-disease patients, especially women.
Blogs
New Data Show Certain Demographics are Denied Cholesterol-Lowering Medication More Often
Medication access remains a hurdle for many patients, especially those prescribed cholesterol-lowering PCSK9 inhibitors.
Graphics
1 in 4 Women
Social media graphic
1 in 4 Hispanic Heart Patients
Social media graphic
1 in 4 Black Heart Patients
Social media graphic
Papers
A Country in Cardiovascular Crisis
Cardiovascular disease has long been the number one overall cause of death in the United States. Forecasts indicate the situation will worsen.
Arizona PCSK9 Report Card - September 2022
Arizona’s rate of heart disease is higher than the national average. Yet insurers are more likely to reject Arizonans’ prescriptions for cholesterol-lowering medication.
Oklahoma PCSK9 Report Card - August 2022
Oklahoma’s rate of heart disease is higher than the national average. Yet insurers are more likely to reject Oklahomans’ prescriptions for cholesterol-lowering medication.
Texas PCSK9 Report Card - August 2022
Texas’ rate of heart disease is higher than the national average. Yet insurers are more likely to reject Texans’ prescriptions for cholesterol-lowering medication.
Mississippi PCSK9 Report Card - August 2022
Mississippi’s rate of heart disease is higher than the national average. Yet insurers are more likely to reject Mississippians’ prescriptions for cholesterol-lowering medication.
Arkansas PCSK9 Report Card - August 2022
Arkansas’ rate of heart disease is higher than the national average. Yet insurers are more likely to reject Arkansans’ prescriptions for cholesterol-lowering medication.
Rejected: How Life-Saving Heart Medication Eludes Women, Southerners & People of Color
Every 36 seconds, someone in the United States dies from cardiovascular disease. In fact, heart disease is the leading cause of death in America, responsible for one in every four adult fatalities. Making sure patients can access medication that protects their hearts should be a top national health care priority. But recent insurance claims data […]
Videos
Rejected: Patients Denied Access to Life-Saving Heart Medicine
When it comes to high cholesterol, access to the right medication could be a matter of life or death.
Lynne Braun, CNP, PhD, Discusses Cardio Health
Lynne Braun, CNP, PhD, discusses the impact of health insurers' prior authorization on cardiovascular patients.